Attenuation of Staphylococcus aureus-induced bacteremia by human mini-antibodies targeting the complement inhibitory protein Efb

Journal of Immunology

Volumn 195, Issue 8, 2015, Pages 3946-3958

  Georgoutsou Spyridonos, Maria ^a   Ricklin, Daniel ^b   Pratsinis, Haris ^a   Perivolioti, Eustathia ^c   Pirmettis, Ioannis ^a   Garcia, Brandon L ^d   Geisbrecht, Brian V ^d   Foukas, Periklis G ^e   Lambris, John D ^b   Mastellos, Dimitrios C ^a   Sfyroera, Georgia ^a  

^a INSTITUTE OF NANOSCIENCE AND NANOTECHNOLOGY   (Greece)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c IASO GENERAL HOSPITAL   (Greece)

^d KANSAS STATE UNIVERSITY   (United States)

^e NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C3D; COMPLEMENT COMPONENT C5A; EXTRACELLULAR FIBRINOGEN BINDING PROTEIN; INTERLEUKIN 6; RECOMBINANT ANTIBODY; RECOMBINANT MINI ANTIBODY A1; RECOMBINANT MINI ANTIBODY A2; RECOMBINANT MINI ANTIBODY A3; RECOMBINANT MINI ANTIBODY A4; RECOMBINANT MINI ANTIBODY B1; RECOMBINANT MINI ANTIBODY B2; RECOMBINANT MINI ANTIBODY B3; RECOMBINANT MINI ANTIBODY B4; RECOMBINANT MINI ANTIBODY C1; RECOMBINANT MINI ANTIBODY C2; RECOMBINANT MINI ANTIBODY C3; RECOMBINANT MINI ANTIBODY C4; UNCLASSIFIED DRUG; BACTERIAL PROTEIN; BACTERIUM ANTIBODY; EFB PROTEIN, STAPHYLOCOCCUS AUREUS; IL6 PROTEIN, HUMAN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL SURVIVAL; CELL KILLING; COMPLEMENT INHIBITION; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG MECHANISM; DRUG SELECTIVITY; DRUG STABILITY; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; IN VIVO STUDY; INFECTION PREVENTION; KIDNEY ABSCESS; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; SINGLE DRUG DOSE; STAPHYLOCOCCAL BACTEREMIA; ANIMAL; ANTAGONISTS AND INHIBITORS; BACTEREMIA; DISEASE MODEL; IMMUNOLOGY; STAPHYLOCOCCUS AUREUS;

ANIMALS; ANTIBODIES, BACTERIAL; BACTEREMIA; BACTERIAL PROTEINS; COMPLEMENT C5A; DISEASE MODELS, ANIMAL; HUMANS; INTERLEUKIN-6; MICE; SINGLE-CHAIN ANTIBODIES; STAPHYLOCOCCUS AUREUS;

EID: 84943520905     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1500966     Document Type: Article

References (45)

1. Lowy, F. D. 1998. Staphylococcus aureus infections. N. Engl. J. Med. 339:520-532.
2. Klevens, R. M., M. A. Morrison, J. Nadle, S. Petit, K. Gershman, S. Ray, L. H. Harrison, R. Lynfield, G. Dumyati, J. M. Townes, et al; Active Bacterial Core surveillance (ABCs) MRSA Investigators. 2007. Invasive methicillinresistant Staphylococcus aureus infections in the United States. JAMA 298:1763-1771.
3. Chambers, H. F., and F. R. Deleo. 2009. Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat. Rev. Microbiol. 7:629-641.
4. Diep, B. A., S. R. Gill, R. F. Chang, T. H. Phan, J. H. Chen, M. G. Davidson, F. Lin, J. Lin, H. A. Carleton, E. F. Mongodin, et al. 2006. Complete genome sequence of USA300, an epidemic clone of community-acquired meticillinresistant Staphylococcus aureus. Lancet 367:731-739.
5. Centers for Disease Control and Prevention. Threat report 2013. Available at: http://www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf.
6. Fowler, V. G., Jr., and R. A. Proctor. 2014. Where does a Staphylococcus aureus vaccine stand? Clin. Microbiol. Infect. 20(Suppl 5):66-75.
7. De Dent, A., H. K. Kim, D. Missiakas, and O. Schneewind. 2012. Exploring Staphylococcus aureus pathways to disease for vaccine development. Semin. Immunopathol. 34:317-333.
8. Mohapatra, S., and H. S. Juan. 2008. Designer monoclonal antibodies as drugs: the state of the art. Expert Rev. Clin. Immunol. 4:305-307.
9. Presta, L. G. 2008. Molecular engineering and design of therapeutic antibodies. Curr. Opin. Immunol. 20:460-470.
10. Nelson, A. L., E. Dhimolea, and J. M. Reichert. 2010. Development trends for human monoclonal antibody therapeutics. Nat. Rev. Drug Discov. 9:767-774.
11. Ballow, M. 2007. Safety of IGIV therapy and infusion-related adverse events. Immunol. Res. 38:122-132.
12. Kobayashi, S. D., and F. R. De Leo. 2011. A MRSA-terious enemy among us: boosting MRSA vaccines. Nat. Med. 17:168-169.
13. Chavakis, T., K. T. Preissner, and M. Herrmann. 2007. The anti-inflammatory activities of Staphylococcus aureus. Trends Immunol. 28:408-418.
14. Ricklin, D., G. Hajishengallis, K. Yang, and J. D. Lambris. 2010. Complement: a key system for immune surveillance and homeostasis. Nat. Immunol. 11:785-797.
15. Foster, T. J. 2005. Immune evasion by staphylococci. Nat. Rev. Microbiol. 3:948-958.
16. Kim, H. K., V. Thammavongsa, O. Schneewind, and D. Missiakas. 2012. Recurrent infections and immune evasion strategies of Staphylococcus aureus. Curr. Opin. Microbiol. 15:92-99.
17. Garcia, B. L., K. X. Ramyar, D. Ricklin, J. D. Lambris, and B. V. Geisbrecht. 2012. Advances in understanding the structure, function, and mechanism of the SCIN and Efb families of Staphylococcal immune evasion proteins. Adv. Exp. Med. Biol. 946:113-133.
18. Hammel, M., G. Sfyroera, D. Ricklin, P. Magotti, J. D. Lambris, and B. V. Geisbrecht. 2007. A structural basis for complement inhibition by Staphylococcus aureus. Nat. Immunol. 8:430-437.
19. Palma, M., D. Wade, M. Flock, and J. I. Flock. 1998. Multiple binding sites in the interaction between an extracellular fibrinogen-binding protein from Staphylococcus aureus and fibrinogen. J. Biol. Chem. 273:13177-13181.
20. Chen, H., D. Ricklin, M. Hammel, B. L. Garcia, W. J. McWhorter, G. Sfyroera, Y. Q. Wu, A. Tzekou, S. Li, B. V. Geisbrecht, et al. 2010. Allosteric inhibition of complement function by a staphylococcal immune evasion protein. Proc. Natl. Acad. Sci. USA 107:17621-17626.
21. Jongerius, I., J. Köhl, M. K. Pandey, M. Ruyken, K. P. Van Kessel, J. A. Van Strijp, and S. H. Rooijakkers. 2007. Staphylococcal complement evasion by various convertase-blocking molecules. J. Exp. Med. 204:2461-2471.
22. Rooijakkers, S. H., K. P. Van Kessel, and J. A. Van Strijp. 2005. Staphylococcal innate immune evasion. Trends Microbiol. 13:596-601.
23. Palma, M., S. Nozohoor, T. Schennings, A. Heimdahl, and J. I. Flock. 1996. Lack of the extracellular 19-kilodalton fibrinogen-binding protein from Staphylococcus aureus decreases virulence in experimental wound infection. Infect. Immun. 64:5284-5289.
24. Jongerius, I., M. Von Köckritz-Blickwede, M. J. Horsburgh, M. Ruyken, V. Nizet, and S. H. Rooijakkers. 2012. Staphylococcus aureus virulence is enhanced by secreted factors that block innate immune defenses. J. Innate Immun. 4:301-311.
25. Knappik, A., L. Ge, A. Honegger, P. Pack, M. Fischer, G. Wellnhofer, A. Hoess, J. Wölle, A. Plückthun, and B. Virnekäs. 2000. Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides. J. Mol. Biol. 296:57-86.
26. Basta, M., and C. H. Hammer. 1991. A rapid FPLC method for purification of the third component of human and guinea pig complement. J. Immunol. Methods 142:39-44.
27. Guthridge, J. M., J. K. Rakstang, K. A. Young, J. Hinshelwood, M. Aslam, A. Robertson, M. G. Gipson, M. R. Sarrias, W. T. Moore, M. Meagher, et al. 2001. Structural studies in solution of the recombinant N-terminal pair of short consensus/complement repeat domains of complement receptor type 2 (CR2/CD21) and interactions with its ligand C3dg. Biochemistry 40:5931-5941.
28. Geisbrecht, B. V., S. Bouyain, and M. Pop. 2006. An optimized system for expression and purification of secreted bacterial proteins. Protein Expr. Purif. 46:23-32.
29. Mollnes, T. E., O. L. Brekke, M. Fung, H. Fure, D. Christiansen, G. Bergseth, V. Videm, K. T. Lappegård, J. Köhl, and J. D. Lambris. 2002. Essential role of the C5a receptor in E coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation. Blood 100:1869-1877.
30. Karlsson, R., P. S. Katsamba, H. Nordin, E. Pol, and D. G. Myszka. 2006. Analyzing a kinetic titration series using affinity biosensors. Anal. Biochem. 349:136-147.
31. Aguado, M. T., J. D. Lambris, G. C. Tsokos, R. Burger, D. Bitter-Suermann, J. D. Tamerius, F. J. Dixon, and A. N. Theofilopoulos. 1985. Monoclonal antibodies against complement 3 neoantigens for detection of immune complexes and complement activation. Relationship between immune complex levels, state of C3, and numbers of receptors for C3b. J. Clin. Invest. 76:1418-1426.
32. Ko, Y. P., X. Liang, C. W. Smith, J. L. Degen, and M. Höök. 2011. Binding of Efb from Staphylococcus aureus to fibrinogen blocks neutrophil adherence. J. Biol. Chem. 286:9865-9874.
33. Guo, R. F., and P. A. Ward. 2005. Role of C5a in inflammatory responses. Annu. Rev. Immunol. 23:821-852.
34. Hammel, M., G. Sfyroera, S. Pyrpassopoulos, D. Ricklin, K. X. Ramyar, M. Pop, Z. Jin, J. D. Lambris, and B. V. Geisbrecht. 2007. Characterization of Ehp, a secreted complement inhibitory protein from Staphylococcus aureus. J. Biol. Chem. 282:30051-30061.
35. Rooijakkers, S. H., M. Ruyken, A. Roos, M. R. Daha, J. S. Presanis, R. B. Sim, W. J. Van Wamel, K. P. Van Kessel, and J. A. Van Strijp. 2005. Immune evasion by a staphylococcal complement inhibitor that acts on C3 convertases. Nat. Immunol. 6:920-927.
36. Chen, H., M. C. Schuster, G. Sfyroera, B. V. Geisbrecht, and J. D. Lambris. 2008. Solution insights into the structure of the Efb/C3 complement inhibitory complex as revealed by lysine acetylation and mass spectrometry. J. Am. Soc. Mass Spectrom. 19:55-65.
37. Ko, Y. P., A. Kuipers, C. M. Freitag, I. Jongerius, E. Medina, W. J. Van Rooijen, A. N. Spaan, K. P. Van Kessel, M. Höök, and S. H. Rooijakkers. 2013. Phagocytosis escape by a Staphylococcus aureus protein that connects complement and coagulation proteins at the bacterial surface. PLoS Pathog. 9:e1003816.
38. Bosmann, M., and P. A. Ward. 2013. The inflammatory response in sepsis. Trends Immunol. 34:129-136.
39. Cheng, A. G., H. K. Kim, M. L. Burts, T. Krausz, O. Schneewind, and D. M. Missiakas. 2009. Genetic requirements for Staphylococcus aureus abscess formation and persistence in host tissues. FASEB J. 23:3393-3404.
40. Schaffer, A. C., and J. C. Lee. 2008. Vaccination and passive immunisation against Staphylococcus aureus. Int. J. Antimicrob. Agents 32(Suppl 1):S71-S78.
41. Verkaik, N. J., C. P. De Vogel, H. A. Boelens, D. Grumann, T. Hoogenboezem, C. Vink, H. Hooijkaas, T. J. Foster, H. A. Verbrugh, A. Van Belkum, and W. J. Van Wamel. 2009. Anti-staphylococcal humoral immune response in persistent nasal carriers and noncarriers of Staphylococcus aureus. J. Infect. Dis. 199:625-632.
42. Dryla, A., S. Prustomersky, D. Gelbmann, M. Hanner, E. Bettinger, B. Kocsis, T. Kustos, T. Henics, A. Meinke, and E. Nagy. 2005. Comparison of antibody repertoires against Staphylococcus aureus in healthy individuals and in acutely infected patients. Clin. Diagn. Lab. Immunol. 12:387-398.
43. Congy-Jolivet, N., A. Probst, H. Watier, and G. Thibault. 2007. Recombinant therapeutic monoclonal antibodies: mechanisms of action in relation to structural and functional duality. Crit. Rev. Oncol. Hematol. 64:226-233.
44. Van Kessel, K. P., J. Bestebroer, and J. A. Van Strijp. 2014. Neutrophil-Mediated Phagocytosis of Staphylococcus aureus. Front. Immunol. 5:467.
45. Serruto, D., R. Rappuoli, M. Scarselli, P. Gros, and J. A. Van Strijp. 2010. Molecular mechanisms of complement evasion: learning from staphylococci and meningococci. Nat. Rev. Microbiol. 8:393-399.